UK Singer Joe Longthorne is Back Performing
British singer Joe Longthorne is back performing this weekend after a one year absence from the stage through illness that left him fighting for his life. The star spent months in the hospital after setbacks following a bone marrow transplant at Manchester Royal Infirmary. The singer was first diagnosed with non-Hodgkin's lymphoma(NHL) in 1989. He believed he had been given the all-clear in 1997, but the cancer returned.
His official website said the 50-year-old, who has fought NHL for years, has been "feeling much stronger and with every day that passes a little more excited that he will be performing again". He will be performing at the Grand Theatre, Blackpool, Easter Day for the first night of his 2006 UK tour, in what should prove a special and emotional night for his many loyal fans. The tour includes several Yorkshire venues, Sheffield and Bradford in May, Leeds in June and finally his home city in July.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
